Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Maki Todo"'
Autor:
Maki Todo, Gou Kaneko, Suguru Shirotake, Yuki Shimada, Shintaro Nakano, Takashi Okabe, Shiho Ishikawa, Masafumi Oyama, Koshiro Nishimoto
Publikováno v:
IJU Case Reports, Vol 3, Iss 1, Pp 17-20 (2020)
Introduction Pembrolizumab cause immune‐related adverse events. We herein report a case of advanced bladder cancer, who treated with pembrolizumab and exhibited intriguing clinical course. Case presentation A 63‐year‐old man with bladder carcin
Externí odkaz:
https://doaj.org/article/4179b20a6c1540ad9fc8050acc34a5ec
Autor:
Maki Todo, Hideyuki Kondo, Taiki Hayashi, Tsukasa Masuda, Takashi Okabe, Go Kaneko, Masafumi Oyama, Suguru Shirotake, Koshiro Nishimoto
Publikováno v:
IJU Case Reports, Vol 2, Iss 5, Pp 272-275 (2019)
Introduction Pazopanib, a tyrosine kinase inhibitor, and nivolumab, an immune checkpoint inhibitor, are both considered to cause hepatotoxicity with different pathophysiology. We report a case in which a patient died of severe hepatotoxicity who was
Externí odkaz:
https://doaj.org/article/35750e8ec9644e23a5f653f671d2810c
Autor:
Suguru Shirotake, Shintaro Nakano, Koshiro Nishimoto, Gou Kaneko, Yuki Shimada, Masafumi Oyama, Takashi Okabe, Maki Todo, Shiho Ishikawa
Publikováno v:
IJU Case Reports, Vol 3, Iss 1, Pp 17-20 (2020)
IJU Case Reports
IJU Case Reports
Introduction Pembrolizumab cause immune-related adverse events. We herein report a case of advanced bladder cancer, who treated with pembrolizumab and exhibited intriguing clinical course. Case presentation A 63-year-old man with bladder carcinoma wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21f326aed3b68480bd3e67cbe896c491
https://doaj.org/article/4179b20a6c1540ad9fc8050acc34a5ec
https://doaj.org/article/4179b20a6c1540ad9fc8050acc34a5ec
Autor:
Taiki Hayashi, Tsukasa Masuda, Koshiro Nishimoto, Suguru Shirotake, Masafumi Oyama, Hideyuki Kondo, Go Kaneko, Maki Todo, Takashi Okabe
Publikováno v:
IJU Case Reports
IJU Case Reports, Vol 2, Iss 5, Pp 272-275 (2019)
IJU Case Reports, Vol 2, Iss 5, Pp 272-275 (2019)
Introduction Pazopanib, a tyrosine kinase inhibitor, and nivolumab, an immune checkpoint inhibitor, are both considered to cause hepatotoxicity with different pathophysiology. We report a case in which a patient died of severe hepatotoxicity who was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f6d47aca80d39c5c0130e16db70fc69
http://europepmc.org/articles/PMC7292132
http://europepmc.org/articles/PMC7292132
Autor:
Yasumori Sujino, Maki Todo, Atsuko Watanabe, Kenji Fukushima, Toshihiro Muramatsu, Ryuhei Tanaka, Shintaro Nakano, Yuki Shimizu, Atsuhiko Ohta, Yodo Gotate, Ken Naganuma
Thrombohemorrhagic disorders are the main cause of morbidities and mortalities of essential thrombocythemia (ET), which are typically observed at age 50–60 years and rarely encountered in adolescence or childhood. Recently, anagrelide, a quinazinol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd192665457b4abc3cd9d1597403e98a
https://doi.org/10.22541/au.158921467.78099904
https://doi.org/10.22541/au.158921467.78099904
Autor:
Nozomu Uchida, Hideki Onishi, Suguru Shirotake, Mayumi Ishida, Maki Todo, Masafumi Oyama, Takashi Okabe
Publikováno v:
Palliative and Supportive Care. 18:241-243
BackgroundNivolumab has become an effective treatment option for cancer in various sites; however, this drug may cause immune-related adverse effects due to its mechanism of action. Furthermore, little has been reported on thiamine deficiency (TD) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee6cf60fb6a444579cf19281051104b4
https://doi.org/10.1017/s1478951519000658
https://doi.org/10.1017/s1478951519000658
Autor:
Hideki Makabe, Hideyuki Kondo, Takashi Okabe, Suguru Shirotake, Maki Todo, Koshiro Nishimoto, Gou Kaneko, Masafumi Oyama, Yota Yasumizu
Publikováno v:
Anticancer research. 39(2)
BACKGROUND Pazopanib is an effective treatment option for renal cell carcinoma (RCC). However, the therapy is often limited by the appearance of adverse events (AEs), including nausea/vomiting, hepatic impairment, hand-foot syndrome, diarrhea, hypert
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15e12ef06146b689eec8ab606c63ba98
https://pubmed.ncbi.nlm.nih.gov/30711987
https://pubmed.ncbi.nlm.nih.gov/30711987
Autor:
Hiromitsu Yabushita, Keita Iwasaki, Akihiko Wakatsuki, Chiharu Suzuki, Mari Nishihara, Miki Kondo, Maki Todo, Shoko Kinoshita, Yoshihiro Yamamoto, Kikuyo Nishida, Kenichi Arai, Kazuyo Kanbara, Katsuhiko Matsuura
Publikováno v:
Palliative Care Research. 8:570-574
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b85c50136cdca83526fcf3ce17e4c5eb
https://doi.org/10.2512/jspm.8.570
https://doi.org/10.2512/jspm.8.570